PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

References

• Surveillance, Epidemiology, and End Results ProgramCancer stat facts: bladder cancer Available from: https://seer.cancer.gov/statfacts/html/urinb.htmlAccessed November 17, 2017
   Google Scholar
• CooksonMSHerrHWZhangZFSolowaySSoganiPCFairWRThe treated natural history of high risk superficial bladder cancer: 15-year outcomeJ Urol1997158162679186324
   PubMed Web of Science ®Google Scholar
• ClarkPNCCN clinical practice guidelines in oncology (NCCN guidelines): bladder cancer Version 12018 Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdfAccessed on May 18, 2018
   Google Scholar
• PectasidesDPectasidesMNikolaouMAdjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature reviewEur Urol2005481606815967253
   PubMed Web of Science ®Google Scholar
• von der MaaseHHansenSWRobertsJTGemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III studyJ Clin Oncol200018173068307711001674
   PubMed Web of Science ®Google Scholar
• SternbergCNde MulderPHSchornagelJHRandomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924J Clin Oncol200119102638264611352955
   PubMed Web of Science ®Google Scholar
• LorussoVPolleraCFAntimiMA phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinumEur J Cancer1998348120812129849481
   PubMed Web of Science ®Google Scholar
• McCaffreyJAHiltonSMazumdarMPhase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinomaJ Clin Oncol1997155185318579164195
   PubMed Web of Science ®Google Scholar
• PapamichaelDGallagherCJOliverRTJohnsonPWWaxmanJPhase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureterBr J Cancer19977546066079052419
   PubMed Web of Science ®Google Scholar
• VaughnDJBroomeCMHussainMGutheilJCMarkowitzABPhase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancerJ Clin Oncol200220493794011844814
   PubMed Web of Science ®Google Scholar
• DashAGalskyMDVickersAJImpact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladderCancer2006107350651316773629
   PubMed Web of Science ®Google Scholar
• GalskyMDHahnNMRosenbergJTreatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapyJ Clin Oncol201129172432243821555688
   PubMed Web of Science ®Google Scholar
• BellmuntJMottetNde SantisMUrothelial carcinoma management in elderly or unfit patientsEJC Suppl201614112027358584
   PubMedGoogle Scholar
• MoralesAEidingerDBruceAWIntracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumorsJ Urol19761162180182820877
   PubMed Web of Science ®Google Scholar
• MoralesATreatment of carcinoma in situ of the bladder with BCGCancer Immunol Immunother198091–26972
   Web of Science ®Google Scholar
• AlexandrovLBNik-ZainalSWedgeDCSignatures of mutational processes in human cancerNature2013500746341542123945592
   PubMed Web of Science ®Google Scholar
• SnyderAMakarovVMerghoubTGenetic basis for clinical response to CTLA-4 blockade in melanomaN Engl J Med2014371232189219925409260
   PubMed Web of Science ®Google Scholar
• RizviNAHellmannMDSnyderACancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerScience2015348623012412825765070
   PubMed Web of Science ®Google Scholar
• RosenbergJEHoffman-CensitsJPowlesTAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialLancet2016387100311909192026952546
   PubMed Web of Science ®Google Scholar
• RibasAReleasing the brakes on cancer immunotherapyN Engl J Med2015373161490149226348216
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationKeytruda (pembrolizumab) [prescribing information]2016 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdfAccessed September 8, 2017
   Google Scholar
• PuzanovIDummerRSchachterJEfficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL)Journal of Clinical Oncology20153315 suppl30123012
   Web of Science ®Google Scholar
• SchachterJRibasALongGVPembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)The Lancet20173901010518531862
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimD-WPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet20163871002715401550
   PubMed Web of Science ®Google Scholar
• LangerCJGadgeelSMBorghaeiHCarboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 studyLancet Oncol201617111497150827745820
   PubMed Web of Science ®Google Scholar
• BellmuntJde WitRVaughnDJPembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaNew England Journal of Medicine2017376111015102628212060
   PubMed Web of Science ®Google Scholar
• PlimackERBellmuntJGuptaSSafety and activity of pembroli-zumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b studyThe Lancet Oncology201718221222028081914
   PubMed Web of Science ®Google Scholar
• BalarAVCastellanoDO’DonnellPHFirst-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyLancet Oncol201718111483149228967485
   PubMed Web of Science ®Google Scholar
• MoskowitzCHZinzaniPLFanaleMAPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 StudyBlood20161282211071107
   Web of Science ®Google Scholar
• SweeneyCJRothBJKabbinavarFFPhase II study of pemetrexed for second-line treatment of transitional cell cancer of the urotheliumJ Clin Oncol200624213451345716849761
   PubMed Web of Science ®Google Scholar
• HarrisJUpdate sustains frontline pembrolizumab benefit in urothelial carcinoma2017 Available from: http://www.onclive.com/web-exclusives/update-sustains-frontline-pembrolizumab-benefit-in-urothelial-carcinomaAccessed January 23, 2018
   Google Scholar
• BalarAVGalskyMDRosenbergJEAtezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialLancet201738910064677627939400
   PubMed Web of Science ®Google Scholar
• Tecentriq (atezolizumab) [prescribing information]2018 Available from: https://www.gene.com/download/pdf/tecentriq_prescribing.pdfAccessed July 20, 2018
   Google Scholar
• PowlesTDuránIvan der HeijdenMSAtezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor 211): a multicentre, open-label, phase 3 randomised controlled trialLancet20183911012274875729268948
   PubMed Web of Science ®Google Scholar
• SharmaPCallahanMKBonoPNivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multi-centre, open-label, two-stage, multi-arm, phase 1/2 trialLancet Oncol201617111590159827733243
   PubMed Web of Science ®Google Scholar
• SharmaPRetzMSiefker-RadtkeANivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multi-centre, single-arm, phase 2 trialLancet Oncol201718331232228131785
   PubMed Web of Science ®Google Scholar
• AstraZenecaImfinzi (durvalumab) [highlights of prescribing information]2017 Available from: https://www.azpicentral.com/imfinzi/imfinzi.pdfAccessed May 1, 2017
   Google Scholar
• PowlesTO’DonnellPHMassardCEfficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label studyJAMA Oncol201739e17241128817753
   PubMed Web of Science ®Google Scholar
• MassardCGordonMSSharmaSSafety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancerJ Clin Oncol201634263119312527269937
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationBavencio (avelumab) [prescribing information]2017 Available from: https://www.accessdata.fda.gov/drug-satfda_docs/label/2017/761049s000lbl.pdfAccessed July 20, 2018
   Google Scholar
• ApoloABInfanteJRBalmanoukianAAvelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase IB studyJ Clin Oncol201735192117212428375787
   PubMed Web of Science ®Google Scholar
• PatelMREllertonJInfanteJRAvelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, phase 1 trialLancet Oncol2018191516429217288
   PubMed Web of Science ®Google Scholar
• PuzanovIDiabAAbdallahKManaging toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working GroupJ Immunother Cancer2017519529162153
   PubMed Web of Science ®Google Scholar
• ChampiatSLambotteOBarreauEManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnn Oncol201627455957426715621
   PubMed Web of Science ®Google Scholar
• HaanenJCarbonnelFRobertCManagement of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201728Suppl 4iv119iv14228881921
   PubMed Web of Science ®Google Scholar
• SeymourLBogaertsJPerroneAiRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLancet Oncol2017183e143e15228271869
   PubMed Web of Science ®Google Scholar
• RoutyBle ChatelierEDerosaLGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsScience20183596371919729097494
   PubMed Web of Science ®Google Scholar
• SivanACorralesLHubertNCommensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacyScience201535062641084108926541606
   PubMed Web of Science ®Google Scholar